Skip to main content
Premium Trial:

Request an Annual Quote

MitoKor Raises $25M in Funding Round

SAN FRANCISCO, Dec. 20 - MitoKor said Thursday it had raised $25 million in private equity funding.


Investors included the San Diego, Calif.-based company's largest shareholders, Alta Partners, Forward Ventures, Domain Associates/3i Bioscience Investment Trust, MDS Capital Corp., and S.R. One, in addition to new investors Federated Kaufmann Fund, Orbitex Health and Biotechnology Funds, Palladin Group, China Development Industrial Bank, First Bio Venture Capital, Emerging Growth Management Funds, and DRW Venture Partners.


In 1997, MitoKor raised $16.1 million in venture capital.


MitoKor is hoping to use its knowledge of mitochondria to develop therapeutic treatments for diseases stemming from aging. The company has completed sequencing the mitochondrial genomes of more than 600 people. 

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.